Welcome to our dedicated page for Cormedix SEC filings (Ticker: CRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CorMedix Inc. (CRMD) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, offering a detailed view of its financial condition, governance, and material events. CorMedix is a Nasdaq Global Market–listed biopharmaceutical company focused on therapeutic products for life-threatening conditions and diseases, including DefenCath for catheter-related bloodstream infection prevention and a portfolio of anti-infective and hospital products acquired through Melinta Therapeutics LLC.
Current reports on Form 8-K document significant developments such as the completion of the Melinta acquisition, the related contingent payment and registration rights agreements, the issuance of convertible senior notes, equity offerings, and preliminary or final quarterly results. For example, a Form 8-K filed on November 12, 2025 furnishes third-quarter 2025 financial results and guidance updates, while earlier 8-Ks describe the Melinta transaction terms and the convertible notes offering used in part to fund the deal.
Proxy statements on Schedule 14A provide insight into CorMedix’s corporate governance and capital structure decisions. A definitive proxy statement filed in October 2025 outlines proposals for a special meeting, including amendments to the company’s stock incentive plan, ratification of certificate of designation amendments, and changes to its certificate of incorporation affecting preferred stock voting rights.
Investors can also use this page to access periodic reports referenced in the company’s proxy and 8-K filings, which contain audited financial statements, risk factors, and management’s discussion and analysis. These filings explain how CorMedix reports revenue from DefenCath and the Melinta portfolio, records goodwill and intangible assets, and accounts for items such as deferred tax assets and non-GAAP measures like adjusted EBITDA.
In addition, insider and capital markets–related filings are available, including disclosures about equity offerings, convertible notes, and voting results from annual and special meetings. Stock Titan’s interface pairs these documents with AI-powered summaries that highlight key points from lengthy 10-K, 10-Q, 8-K, and proxy materials, helping users quickly understand transaction terms, clinical program disclosures, and changes in guidance without reading every page.
CorMedix Inc: The Vanguard Group filed an amendment to its Schedule 13G reporting that, after an internal realignment, certain Vanguard subsidiaries will report holdings separately and The Vanguard Group now reports 0 shares and 0% ownership of CorMedix common stock as of the amendment. The filing explains the disaggregation is in accordance with SEC Release No. 34-39538 and is signed by Vanguard's Head of Global Fund Administration on 03/26/2026.
CorMedix Inc. furnished an updated investor presentation and reaffirmed its prior guidance that full-year 2027 DefenCath sales are estimated at $100–$140 million, clarifying an inadvertent reference to $100–$125 million on a recent earnings call. The presentation outlines a broader growth plan, including 2026 revenue guidance of $300–$320 million and adjusted EBITDA of $100–$125 million, driven by DefenCath and a diversified anti-infective portfolio. Pro forma 2025 net revenue is shown at $401 million, with Q4 2025 DefenCath sales of $91 million and 79.1 million common shares outstanding as of December 31, 2025. CorMedix also highlights late-stage expansion opportunities for DefenCath in total parenteral nutrition and for REZZAYO in fungal prophylaxis, alongside a cash and short-term investment balance of $149 million.
CorMedix Inc. reports a transformational 2025, moving to net income of $163.1 million from a $17.9 million loss in 2024, while carrying an accumulated deficit of $176.6 million as of December 31, 2025.
Growth is led by DefenCath, its first-in-class antimicrobial catheter lock, launched across U.S. hemodialysis settings in 2024 and now the largest contributor to net sales. The August 2025 acquisition of Melinta Therapeutics adds six marketed hospital anti-infectives plus cardiovascular drug TOPROL-XL, creating a broader acute-care portfolio.
DefenCath benefits from Medicare NTAP and ESRD TDAPA, but reimbursement will reset as NTAP ends in November 2026 and TDAPA shifts to a post-TDAPA add-on in July 2026, which the company expects to pressure net pricing in late 2026. CorMedix is also investing in label expansion for DefenCath and REZZAYO and advancing BARDA-supported pediatric and biothreat programs while relying on third-party manufacturing and extensive intellectual property and exclusivity protections.
CorMedix Inc. reported a strong finish to 2025, with fourth-quarter net revenue of $128.6 million, including $91.2 million from DefenCath and $37.4 million from the newly acquired Melinta portfolio, up sharply from $31.2 million in the prior-year quarter.
For full-year 2025, total revenue rose to $311.7 million and pro forma revenue, assuming a full year of Melinta, reached $401.3 million. The company generated net income of $163.1 million, or $2.04 per diluted share, reversing a $17.9 million loss in 2024, and delivered adjusted EBITDA of $77.2 million in Q4 2025. Operating expenses roughly doubled as CorMedix absorbed Melinta and invested in DefenCath and late-stage studies, while cash, cash equivalents and short-term investments totaled $148.5 million as of December 31, 2025.
CorMedix Inc. insider filing shows a new equity award to its Chief Legal Officer. Beth Zelnick Kaufman received 36,006 shares of common stock on February 4, 2026 at a price of $0.00, following achievement of performance stock unit (PSU) goals for the first of three performance periods.
The PSUs were originally granted on January 2, 2025 and remain subject to additional time-based vesting conditions before fully vesting. After this award, she beneficially owns 269,108 shares of CorMedix common stock directly.
CorMedix Inc. Chief Operating Officer Elizabeth Hurlburt reported an equity-related award linked to performance stock units. On 02/04/2026, she acquired 36,006 shares of CorMedix common stock at a reported price of $0.00, increasing her beneficial ownership to 278,539 directly held shares.
The filing explains this reflects achievement of performance stock units granted on January 2, 2025, after the Compensation Committee determined that performance conditions for the first of three performance periods were met. These units remain subject to additional time-based vesting requirements for Hurlburt.
CorMedix Inc. reported an equity award to its Chief Executive Officer and director Joseph Todisco. On February 4, 2026, he acquired 77,156 shares of common stock at $0.00 per share, following the achievement of performance stock units for the first of three performance periods granted on January 2, 2025.
After this transaction, Todisco beneficially owned 774,749 shares of CorMedix common stock, held directly. The performance stock units remain subject to time-based vesting conditions that must be satisfied by the reporting person before full vesting.
CorMedix Inc. Chief Financial Officer Susan Blum reported equity compensation and related share withholding transactions. On 01/23/2026, she was granted 72,820 restricted stock units, each representing one share of CorMedix common stock at a stated price of $0.00.
The restricted stock units vest 1/4 on the grant date and, subject to continued employment, 1/4 on each of the first, second, and third anniversaries of the grant. On the same date, 9,767 shares of common stock were disposed of at $7.27 per share in a transaction coded "F," typically indicating shares withheld to cover taxes. After these transactions, Blum directly owned 132,739 shares of CorMedix common stock.
CorMedix Inc.'s Chief Legal Officer Beth Zelnick Kaufman reported equity compensation activity in the company’s common stock. On 01/23/2026 she received an award of 72,820 restricted stock units at a price of $0.00 per unit, each representing one share of common stock.
The restricted stock units vest 25% on the grant date and, subject to continued employment, 25% on each of the first, second, and third anniversaries of the grant date. On the same day, 8,803 shares were withheld at $7.27 per share, typically for tax obligations, leaving her with 233,102 directly owned shares after the reported transactions.
CorMedix Inc. Chief Operating Officer Elizabeth Hurlburt reported equity compensation and a related share sale. On 01/23/2026 she received 93,010 shares of common stock for $0.00 per share as a grant of restricted stock units that convert into common stock.
The restricted stock units vest 1/4 at grant and, subject to continued employment, 1/4 on each of the first, second, and third anniversaries of the grant date. On the same day, 10,778 shares of common stock were disposed of at $7.27 per share, typically reflecting shares withheld or sold to cover taxes, leaving her with 242,533 directly owned shares.